Cargando…

Remdesivir and COVID-19 infection, therapeutic benefits or unnecessary risks?

Detalles Bibliográficos
Autores principales:	Vitiello, Antonio, Ferrara, Francesco, Porta, Raffaele La
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7801863/ https://www.ncbi.nlm.nih.gov/pubmed/33433843 http://dx.doi.org/10.1007/s11845-020-02482-2

Ejemplares similares

Remdesivir and COVID-19
por: Ferrara, Francesco, et al.
Publicado: (2020)

Remdesivir versus ritonavir/lopinavir in COVID-19 patients
por: Vitiello, Antonio, et al.
Publicado: (2020)

COVID-19 vaccination in pregnancy
por: Vitiello, Antonio, et al.
Publicado: (2021)

COVID-19 pandemic: vaccine and new monoclonal antibodies, point of view
por: Vitiello, Antonio, et al.
Publicado: (2021)

Perspectives of association Baricitinib/Remdesivir for adults with Covid-19 infection
por: Vitiello, Antonio, et al.
Publicado: (2021)

Are multiple sclerosis therapies safe in severe acute respiratory syndrome coronavirus 2 times?
por: Ferrara, Francesco, et al.
Publicado: (2020)

Association and pharmacological synergism of the triple drug therapy baricitinib/remdesivir/rhACE2 for the management of COVID-19 infection
por: Vitiello, Antonio, et al.
Publicado: (2021)

Anti-fibrotic therapy for the treatment of pulmonary sequelae in patients healed by COVID-19
por: Vitiello, Antonio, et al.
Publicado: (2021)

COVID-19 global pandemic: vaccines and new monoclonal antibodies, aspects to be clarified
por: Ferrara, Francesco, et al.
Publicado: (2021)

Nirmatrelvir–remdesivir association for non-hospitalized adults with COVID-19, point of view
por: Ferrara, Francesco, et al.
Publicado: (2022)

Scientific hypothesis and rational pharmacological for the use of sacubitril/valsartan in cardiac damage caused by COVID-19
por: Vitiello, Antonio, et al.
Publicado: (2021)

The risks of liver injury in COVID-19 patients and pharmacological management to reduce or prevent the damage induced
por: Vitiello, Antonio, et al.
Publicado: (2021)

Excessive anxiety in IBD patients is unnecessary for COVID-19
por: Wang, Hong-Gang, et al.
Publicado: (2020)

Liver injury in remdesivir-treated COVID-19 patients
por: Zampino, Rosa, et al.
Publicado: (2020)

Pulmonary administration of remdesivir in the treatment of COVID-19
por: Rasmussen, Henrik Berg, et al.
Publicado: (2020)

Remdesivir for COVID-19: Why Not Dose Higher?
por: Yan, Victoria C., et al.
Publicado: (2021)

Remdesivir for the treatment of COVID-19: author's response
por: Lee, Todd C., et al.
Publicado: (2023)

Remdesivir in moderate to severe COVID-19: A matter of time?
por: Bonazzetti, Cecilia, et al.
Publicado: (2021)

Treatment of patients with COVID-19 on hemodialysis: Efficacy of remdesivir
por: Nakaya, Aya, et al.
Publicado: (2022)

Treatment of patients with COVID-19 on hemodialysis: Efficacy of remdesivir
por: Nakaya, Aya, et al.
Publicado: (2023)

Controversies on the Stethoscope During COVID-19: A Necessary Tool or an Unnecessary Evil?
por: Patel, Love, et al.
Publicado: (2021)

Benefit-risk assessment for remdesivir in COVID-19
Publicado: (2020)

Response to “Unnecessary spinal surgery”
por: Watts, Clark
Publicado: (2011)

Misclassification bias and unnecessary anxiety
por: Knight, Marian, et al.
Publicado: (2021)

Indian perspective of remdesivir: A promising COVID-19 drug
por: Singh, Devendra, et al.
Publicado: (2020)

Re: Remdesivir for the treatment of COVID-19 by Lee et al.
por: Beccacece, Alessia, et al.
Publicado: (2023)

Remdesivir modifies interferon response in hospitalized COVID-19 patients
por: Murphy, Sarah L., et al.
Publicado: (2022)

Risk of drug-induced cardiac arrhythmia during COVID-19 therapeutic treatment
por: Vitiello, Antonio, et al.
Publicado: (2021)

A Patient with X-Linked Agammaglobulinemia and COVID-19 Infection Treated with Remdesivir and Convalescent Plasma
por: Iaboni, Aled, et al.
Publicado: (2021)

Remdesivir treatment and transient bradycardia in patients with coronavirus diseases 2019 (COVID-19)
por: Pallotto, Carlo, et al.
Publicado: (2021)

Remdesivir in Breastfeeding
por: Sadati, Elham, et al.
Publicado: (2022)

Does Remdesivir maintain the race in the general treatment protocol of COVID-19?
por: Thangaraju, Pugazhenthan, et al.
Publicado: (2021)

Reply to Yan and Muller, “Remdesivir for COVID-19: Why Not Dose Higher?”
por: Juneja, Kavita, et al.
Publicado: (2021)

What will be the role of molnupiravir in the treatment of COVID-19 infection?
por: Vitiello, Antonio, et al.
Publicado: (2021)

Anaphylaxis Due to Remdesivir
por: Hopkins, Brian J., et al.
Publicado: (2021)

Quality of adverse event reporting in clinical trials of remdesivir in patients with COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2020)

Painful Blisters of Left Hand Following Extravasation of Remdesivir Infusion in COVID-19
por: Kumar, Neeraj, et al.
Publicado: (2021)

COVID-19 and Alcohol Consumption: No Preventive or Therapeutic Benefits
por: Shrivastava, Saurabh RamBihariLal, et al.
Publicado: (2020)

Remdesivir for COVID-19 pneumonia: still undecided, but it might all be about adequate timing
por: Trkulja, Vladimir
Publicado: (2021)

Prediction of remdesivir resistance in COVID-19 illness: Need for development of clinical laboratory test
por: Kumar, Deepak, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qhikpg91qje8jr42k23ga01nl6